SCHEMBL29344133

SCHEMBL29344133

NC(=O)Nc1c(F)cc(F)cc1C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 2/20 0.42
CES2 O00748 5/20 0.41
CES1 P23141 5/20 0.41
ALDH1A1 P00352 5/20 0.40
KIF11 P52732 1/20 0.37
KMT2A Q03164 3/20 0.36
MAPT P10636 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
MEN1 O00255 2/20 0.35
GAA P10253 1/20 0.35
IKBKB O14920 1/20 0.35
JAK2 O60674 1/20 0.35
EIF2AK2 P19525 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
KDM4E B2RXH2 2/20 0.34
USP2 O75604 1/20 0.34
DHFR P00374 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5154372 0.85 ALDH1A1 (0.48) CES2CES1ALDH1A1KIF11KMT2A
SCHEMBL29344273 0.83 CYP3A4 (0.43) KEAP1ALDH1A1KDM4ECA1CA2
SCHEMBL7541890 0.71 KEAP1 (0.55) KEAP1ALDH1A1KIF11MAPTSMN1; SMN2
SCHEMBL2060245 0.71 KEAP1 (0.53) KEAP1CES2CES1ALDH1A1KMT2A
SCHEMBL7542359 0.70 STING1 (0.48) KIF11KMT2AMAPTMEN1TDP1
SCHEMBL2092769 0.70 RAPGEF4 (0.42) CES2CES1ALDH1A1KMT2AMAPT
SCHEMBL1421628 0.70 CES2 (0.71) KEAP1CES2CES1ALDH1A1KMT2A
SCHEMBL15635392 0.69 CES2 (0.36) KEAP1CES2CES1ALDH1A1KMT2A
SCHEMBL29116317 0.69 MPO (0.49) KMT2AMEN1JAK2LMNAHPGD
SCHEMBL10878808 0.69 CDC7 (0.37) KEAP1CES2CES1HDAC6KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-07-18 US disclosed
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-07-18 US disclosed
EP-4322954-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT Merck Sharp & Dohme LLC (US) 2024-02-21 EP disclosed
WO-2022221739-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT MERCK SHARP & DOHME CORP. (US) 2022-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT KRAS, NRAS, HRAS KEAP1 410/4885CES2 4853/4885CES1 4289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.